Neurogene (NGNE) Payables (2013 - 2026)

Neurogene (NGNE) has 11 years of Payables data on file, last reported at $4.7 million in Q1 2026.

• Quarterly Payables rose 52.95% year-over-year to $4.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.7 million (up 52.95% YoY) and the FY2025 annual result came in at $2.0 million, up 46.18% from the prior year.
• Payables grew to $4.7 million in Q1 2026, from $2.0 million in the prior quarter.
• In the past five years, Payables ranged from a high of $8.9 million in Q3 2022 to a low of $625000.0 in Q4 2022.
• A 5-year average of $3.4 million and a median of $2.6 million in 2023 frame the typical range for Payables.
• Annual changes were most pronounced in 2022 — Payables plunged 91.57% — and 2023, when it surged 315.36%.
• Tracing NGNE's Payables over 5 years: stood at $625000.0 in 2022, then surged by 315.36% to $2.6 million in 2023, then plunged by 48.54% to $1.3 million in 2024, then surged by 46.18% to $2.0 million in 2025, then soared by 139.89% to $4.7 million in 2026.
• The last three Payables figures came in at $4.7 million (Q1 2026), $2.0 million (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.